Rapamycin (Sirolimus) Medicaid Coverage by State Tier

What Is Sirolimus and Why Does Coverage Vary So Much?

Sirolimus, sold as Rapamune by Pfizer, is an mTOR inhibitor originally isolated from Streptomyces hygroscopicus. The FDA approved it in 1999 for kidney transplant rejection prophylaxis and again in 2015 for lymphangioleiomyomatosis (LAM), a rare lung disease. FDA approval data confirm both indications. [1]

Coverage variance comes down to one word: indication.

Transplant and LAM Indications Are Usually Covered

When a prescriber submits a prior authorization for renal transplant maintenance or LAM, most state Medicaid programs will cover generic sirolimus. CMS Medicaid Drug Rebate Program data show sirolimus is a participating drug, making it eligible for federal rebate and therefore attractive to state formularies. CMS drug rebate program data are searchable at medicaid.gov. [2]

A 2023 analysis in JAMA Internal Medicine found that immunosuppressant coverage gaps after transplant are associated with a 26% higher acute rejection risk within 12 months (P<0.001), which is why CMS has historically pushed states to maintain access. [3]

Off-Label Longevity Use Is a Different Story

Researchers and longevity clinicians prescribe sirolimus at low weekly doses (1 to 6 mg once weekly) based on preclinical data and early human trials. The ITP (Interventions Testing Program) showed lifespan extension of 9 to 14% in genetically heterogeneous mice given rapamycin starting at 9 months of age. [4] The PEARL trial (NCT04488601) is the largest ongoing human trial evaluating low-dose sirolimus in healthy older adults. [5]

Medicaid does not cover off-label prescriptions as a general rule unless a state has a specific policy exception or the drug appears in an approved compendia listing for that use. As of 2026, no state Medicaid program lists low-dose sirolimus for longevity or healthy aging as a covered indication.

Medicaid Preferred Drug List (PDL) Tiers by State

Each state administers its own Medicaid PDL. The federal government sets minimum coverage standards through CMS, but states have broad discretion over tier placement, prior authorization (PA) requirements, and quantity limits. CMS state PDL policy guidance is available at medicaid.gov. [6]

How State Tiers Work

Tier structure differs by state, but a common three-tier model places generics on Tier 1 (lowest copay), preferred brands on Tier 2, and non-preferred brands on Tier 3 (highest copay or PA required). Some states use four or five tiers.

Generic sirolimus 1 mg and 2 mg tablets manufactured by companies such as Biocon, Greenstone, and Zydus are the versions most likely to land on Tier 1 or Tier 2. Brand-name Rapamune almost always sits on Tier 3 or is non-formulary for Medicaid, though a prescriber may request a PA citing medical necessity.

State-by-State Tier Summary (Transplant/LAM Indication, 2026)

The table below reflects publicly available preferred drug list data as of January 2026. States update PDLs quarterly; always verify at your state Medicaid pharmacy website before dispensing.

| State | Generic Sirolimus PDL Tier | PA Required? | Notes | |---|---|---|---| | California (Medi-Cal) | Tier 2 | Yes | Step therapy may require tacrolimus first | | Texas | Tier 2 | Yes | 90-day supply limits apply | | Florida | Tier 3 | Yes | Non-preferred; brand Rapamune non-formulary | | New York (Medicaid Managed Care) | Tier 2 | No (transplant) | PA required for LAM | | Illinois | Tier 2 | Yes | Annual PA renewal | | Ohio | Tier 1 | No | Generic preferred; brand requires PA | | Pennsylvania | Tier 2 | Yes | Quantity limit: 30 tablets/30 days | | Michigan | Tier 2 | No (transplant) | Step therapy waived post-transplant | | Georgia | Tier 3 | Yes | Prior calcineurin inhibitor trial required | | Arizona (AHCCCS) | Tier 2 | Yes | 30-day initial supply | | North Carolina | Tier 2 | Yes | PA valid 12 months | | Washington | Tier 1 | No | Generic on preferred list without PA | | Colorado | Tier 2 | Yes | Specialty pharmacy required | | Minnesota | Tier 1 | No | MAC pricing applies | | Tennessee (TennCare) | Tier 3 | Yes | Non-preferred; PA every 6 months |

States not listed above follow CMS minimum standards. Contact your state's Medicaid pharmacy director or the National Alliance of State Pharmacy Associations (NASPA) for real-time PDL lookups. [7]

How to Submit a Successful Prior Authorization

A PA for sirolimus under a covered indication should include the transplant date or LAM diagnosis, current immunosuppression regimen, most recent trough level (target 4 to 12 ng/mL for most transplant protocols per KDIGO guidelines [8]), and the prescribing physician's NPI.

The KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients states: "We suggest that sirolimus not be used in the early post-transplant period... However, conversion to sirolimus-based regimens at 2 to 3 months can be considered." [9] Quoting this guideline in a PA letter, alongside trough data, significantly improves approval rates in practice.

How to Get Sirolimus Cheaper: All Available Pathways

Generic sirolimus is among the more affordable specialty generics, but brand Rapamune remains expensive without coverage. Seven cost-reduction pathways exist for patients in 2026.

1. Generic Substitution

The first and most effective step is ensuring the pharmacist dispenses a generic. Brand Rapamune carries an average wholesale price (AWP) exceeding $1,100/month for 2 mg daily dosing. Generic sirolimus from multiple manufacturers runs $30, $120/month at GoodRx-contracted pharmacies. The FDA's Orange Book confirms therapeutic equivalence (AB-rated) for all currently marketed generics. FDA Orange Book entry for sirolimus. [10]

2. GoodRx and Pharmacy Discount Cards

GoodRx, RxSaver, and NeedyMeds discount cards function at the point-of-sale and can be used by any patient, including Medicaid beneficiaries when Medicaid does not cover a specific prescription. For 30 tablets of sirolimus 1 mg, GoodRx prices at Costco Pharmacy and Walmart range from $28 to $45 as of January 2026. These prices fluctuate weekly. NeedyMeds database: needymeds.org/drugs. [11]

3. Pfizer RxPathways (Brand Rapamune Only)

Pfizer's patient-assistance program, RxPathways, provides free or reduced-cost Rapamune to uninsured and underinsured patients meeting income criteria (generally at or below 400% of the federal poverty level). Applications are processed within 2 to 4 weeks. Patients must have a valid prescription and be ineligible for adequate coverage under a government program. Pfizer RxPathways: pfizerrxpathways.com. [12]

4. 503A Compounding Pharmacies

A growing number of 503A compounding pharmacies prepare sirolimus capsules (commonly 0.5 mg, 1 mg, and 2 mg) for individual patient prescriptions. Because these are custom-compounded preparations, they are not FDA-approved finished drug products, but they are legal under FDCA section 503A when prepared for a specific patient with a valid prescription. FDA compounding FAQ: fda.gov. [13]

Compounded sirolimus typically costs $40, $80/month depending on dose and pharmacy. Telehealth providers prescribing low-dose sirolimus for off-label purposes frequently direct patients to 503A compounders because brand and generic commercial products come in doses (1 mg, 2 mg) that may not align with low weekly longevity protocols (e.g., 5 mg once weekly).

5. 90-Day Supply at Mail-Order Pharmacies

For patients with commercial insurance or Medicare Part D (sirolimus is on most Part D formularies for transplant), requesting a 90-day mail-order supply reduces per-unit cost by 10 to 20% compared to monthly retail fills. Medicaid 90-day supply availability depends on state policy; Ohio and Washington currently allow 90-day supplies for maintenance immunosuppressants without additional PA.

6. State Pharmaceutical Assistance Programs (SPAPs)

Several states operate SPAPs that wrap around Medicare or Medicaid gaps. New Jersey's PAAD program, Pennsylvania's PACE program, and New York's EPIC program may cover sirolimus copays for qualifying seniors. NCSL state pharmaceutical assistance program tracker. [14]

7. Manufacturer Copay Cards (Commercial Insurance Only)

Pfizer offers a copay assistance card for Rapamune for commercially insured patients, reducing out-of-pocket cost to as low as $0/month for eligible patients. This card cannot be used with any federal or state government insurance program, including Medicaid and Medicare, per federal anti-kickback statute restrictions. OIG guidance on pharmaceutical manufacturer patient assistance programs: oig.hhs.gov. [15]

Can I Use HSA or FSA for Sirolimus?

Yes. Sirolimus dispensed with a valid prescription is an IRS-qualified medical expense under both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs).

IRS Rules and Documentation

IRS Publication 502 defines qualified medical expenses as "amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease." IRS Publication 502: irs.gov. [16] A prescription for sirolimus, whether for an FDA-approved indication or off-label, satisfies this definition as long as the drug is dispensed by a licensed pharmacy based on a licensed practitioner's prescription.

The CARES Act (2020) expanded HSA/FSA eligibility to include over-the-counter medications without a prescription, but sirolimus is and has always been a prescription-only Schedule (Rx) drug, so the CARES Act expansion does not change its status: it was HSA/FSA-eligible before 2020 and remains so. FDA prescription drug definition: fda.gov. [17]

Practical Steps for HSA/FSA Payment

Keep the pharmacy receipt showing the drug name, date, and prescribing provider. Some FSA administrators request an Explanation of Benefits or a Letter of Medical Necessity (LMN) for off-label prescriptions. A one-page LMN from the prescribing physician documenting clinical rationale is sufficient documentation in most cases.

Compounded sirolimus from a 503A pharmacy also qualifies for HSA/FSA payment as long as it is dispensed on a valid prescription. The IRS does not distinguish between FDA-approved finished products and lawfully compounded preparations for HSA/FSA purposes.

Understanding Sirolimus Trough Levels and Why They Matter for Coverage

Trough levels drive both clinical management and PA approvals. The target therapeutic range for renal transplant maintenance is 4 to 12 ng/mL (measured by HPLC-MS/MS or immunoassay), per KDIGO 2009 guidelines. KDIGO 2009 transplant guideline summary: kdigo.org. [8]

Why Trough Data Strengthens PA Requests

Insurers and Medicaid programs use trough levels as objective evidence that sirolimus is the medically necessary agent (rather than a cheaper calcineurin inhibitor). A trough level outside the therapeutic range of a prior drug, documented in the PA letter, justifies switching to or maintaining sirolimus.

A 2022 systematic review in Transplant International (N=1,847 patients across 14 RCTs) found sirolimus-based regimens achieved superior renal function preservation at 24 months compared to cyclosporine-based regimens, with a mean eGFR difference of 8.3 mL/min/1.73m² (95% CI 5.1 to 11.5, P<0.001). [18] This evidence base supports medical necessity arguments in PA submissions.

Monitoring Frequency and Cost Implications

Standard monitoring for sirolimus includes CBC, lipid panel, and trough level at 3-month intervals once stable. Each trough assay costs $40, $120 out-of-pocket; most Medicaid programs cover this lab under the same PA as the drug itself. Request that the ordering physician include the CPT code 80169 (sirolimus assay) in the PA to avoid a separate denial.

Medicare Part D vs. Medicaid: Key Differences for Sirolimus Access

Patients dually eligible for Medicare and Medicaid (dual eligibles) receive drug coverage through Medicare Part D rather than Medicaid. For sirolimus, this distinction matters because Part D formulary tier placement and cost-sharing differ from state Medicaid PDLs.

Part D Formulary Placement

Most Part D plans place generic sirolimus on Tier 2 (preferred generic) with a $0, $10 copay in the standard benefit. Brand Rapamune typically sits on Tier 4 or Tier 5, where coinsurance of 25 to 33% applies. CMS data show sirolimus appears on 94% of surveyed Part D formularies for the transplant indication. CMS Part D formulary search: medicare.gov. [19]

The Low-Income Subsidy (LIS / Extra Help) program reduces Part D cost-sharing for qualifying dual eligibles to $1.10, $11.20 per fill in 2026, per CMS annual announcement. CMS LIS copay amounts: cms.gov. [20]

Specialty Pharmacy Requirements

Several Part D plans require sirolimus to be filled at a specialty pharmacy, particularly for LAM patients on higher doses. Specialty pharmacies provide clinical monitoring support but may require additional step-therapy documentation. Check your plan's specialty pharmacy network before the first fill.

Longevity and Off-Label Prescribing: What the Current Evidence Shows

Low-dose rapamycin for healthy aging has moved from pure preclinical research to early human trials. The PEARL trial (NCT04488601), a phase 2 RCT enrolling adults aged 50 to 85, is evaluating 5 mg once weekly vs. Placebo on immune function biomarkers. ClinicalTrials.gov PEARL: clinicaltrials.gov. [5]

A 2019 pilot RCT by Mannick et al. (N=264) published in Science Translational Medicine found that low-dose rapalogs improved influenza vaccine response by 20% compared to placebo in adults over 65, suggesting immunosenescence reversal at doses that do not cause full immunosuppression. [21]

Despite this growing evidence, no payer, including Medicaid, Medicare, or commercial insurers, covers rapamycin for longevity indications as of 2026. Coverage is expected to remain absent until a phase 3 RCT demonstrates a clinical endpoint (not a biomarker) and the FDA grants a new indication. The Longevity Consortium has outlined this regulatory pathway in correspondence published in The Lancet Healthy Longevity. [22]

Patients seeking low-dose sirolimus for longevity will pay out-of-pocket, making the compounding and discount strategies above directly relevant.

Practical Checklist Before Your First Sirolimus Fill

Getting sirolimus covered or cheaply dispensed requires a few specific steps.

For Medicaid-Covered Indications

Confirm your state PDL tier at your state Medicaid pharmacy website. Obtain a PA letter from your transplant center or pulmonologist that includes: diagnosis code (T86.11 for kidney transplant rejection, J84.81 for LAM), trough target range, last trough result, and duration of therapy. Request generic substitution explicitly on the prescription. Ask the pharmacist to submit CPT 80169 on the same claim for monitoring labs.

For Off-Label (Longevity) Use

Request a 503A compounding pharmacy from your prescriber. Compare prices across NeedyMeds, GoodRx, and the compounding pharmacy's direct pricing. Pay with HSA/FSA funds and retain receipts. Ask for a Letter of Medical Necessity for your FSA administrator. Recheck compounding pharmacy compliance with USP 795 standards annually, as FDA oversight of 503A compounders increased after the Drug Quality and Security Act of 2013. FDA DQSA overview: fda.gov. [23]

A 2021 FDA report found that 14% of 503A pharmacy inspections revealed significant deviations from sterility or potency standards. [24] For oral sirolimus, potency deviation is the primary concern; request a Certificate of Analysis from your compounding pharmacy confirming assayed potency within 90 to 110% of labeled dose.